Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.

Pegylated-IFN and ribavirin remains the current treatment for chronic HCV infection in patients co-infected with HIV-1, but this regimen has low efficacy rates, particularly for HCV genotype 1/4 infection, has severe side effects and is extremely costly. Therefore, accurate prediction of treatment response is urgently required. We have recently shown that the NK cell gene, KIR2DS3 and a SNP associated with the IL28B gene synergise to increase the risk of chronic infection in primary HCV mono-infected patients. Identification of SNPs associated with the IL28B gene has also proven very powerful for predicting patient response to treatment. Patients co-infected with HIV-1 are of particular concern given they respond less well to HCV treatment, have more side effects and suffer a more rapid liver disease progression. In this study, we examined both IL28B and KIR2DS3 for their ability to predict treatment response in a cohort of HIV-1/HCV co-infected patients attending two treatment centres in Europe. We found that variation in both host genetic risk factors, IL28B and KIR2DS3, was strongly associated with sustained virological response (SVR) to treatment in our co-infected cohort (n = 149). The majority of patients who achieved a rapid virological response (RVR) achieved a SVR. However, it is currently impossible to predict treatment outcome in patients who fail to achieve an RVR. In our cohort, the presence of host genetic risk factors, IL28B-T and KIR2DS3 alleles, resulted in increased odds of treatment failure in these RVR negative patients (n = 88). Our data suggests that testing for host genetic factors will improve predicting treatment responsiveness in the clinical management of co-infected patients, and provides further evidence of the importance of the innate immune system in the immune response to HCV.

Introduction

Significant advances have been made in the treatment of Hepatitis C virus (HCV) infection but challenges remain for patients that are co-infected with HCV and HIV-1 [1]. Co-infected patients have an accelerated progression of liver fibrosis [2], with consequent higher rates of cirrhosis, liver failure and hepatocellular carcinoma [3]. In addition sustained virologic response (SVR) rates to pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) are inferior when compared to HCV mono-infected patients with overall SVR rates of just 40–50% [3]. Presently PEG-IFN/RBV remains the standard of care for treatment of chronic HCV infection in co-infected patients, as direct acting antivirals (DAAs), such as telaprevir and boceprevir [4]–[6], are not yet approved for the treatment of co-infected individuals. To date there are few studies on the use of DAAs in co-infection, and their role and safe utilisation in this complex patient cohort requires further characterisation [7].

Given the high frequency of non-responsiveness to therapy and the toxicity and high cost of lengthy treatment schedules, identifying patients that are unlikely to achieve SVR to IFN-based treatment is extremely important from both patient care and economic stand-points [3]. Many host (age, liver fibrosis stage, pre-treatment IP10 levels) and viral factors (HCV genotype, baseline HCV-RNA levels) are known to influence likelihood of SVR. Additionally the ‘on-therapy’ viral kinetic response is a key determinant of treatment outcome. In particular achieving a rapid virological response (RVR) is the strongest of all predictors for SVR [8]. However, for some patients failure to do so does not preclude a successful SVR upon completion of therapy [8]. Identification of patients that are unlikely to respond to further treatment in the ‘RVR negative’ group would be of significant benefit to patients and clinicians enabling earlier treatment discontinuation and prioritisation for emerging therapies.

Discovery and validation of single nucleotide polymorphisms (SNPs) within the IL28B genetic region that strongly predict both spontaneous clearance and primary outcome to treatment has been a major breakthrough in the management of patients with Hepatitis C virus (HCV) infection [9]–[11]. We recently reported that the IL28B associated SNP, rs12979860, predicted spontaneous HCV viral clearance in a cohort of Irish patients mono-infected with HCV from contaminated anti-D blood products [12]. We found that the IL28B-T allele had a dominant effect in predicting the development of chronic HCV infection as the presence of an IL28B-T allele, either on its own or in a heterozygous state, was sufficient to confer an increased risk. We also identified a second genetic locus, the NK cell gene KIR2DS3, which predicted an increased risk of chronic HCV infection. There is substantial evidence emerging to support a role for NK cells during HCV infection [13]–[15]. The presence of these two risk factors synergised to increase the risk of developing chronic HCV infection over either risk factor alone. In the current study, we hypothesised that variation in IL28B and KIR2DS3 genetic loci could improve identification of patients that achieve SVR in HCV/HIV-1 co-infected patients and furthermore, could potentially be used to identify those patients that despite not achieving RVR will ultimately go on to achieve an SVR.

Materials and Methods

Patients

Fully informed written consent was obtained from all participants and the study was granted local ethical approval from St. James’s Hospital Research Ethical Committee (Dublin) and the Ethics Committee of the Medical University of Vienna (Vienna). The study population comprised 149 HCV/HIV-1 co-infected patients attending specialist HCV/HIV co-infection clinics between June 2001 and December 2010, 71 in Dublin, Ireland and 78 in Vienna, Austria. Patient characteristics are shown in Table 1. HCV/HIV-1 co-infected patients were treated with pegylated-interferon alpha 2b 1.5 µg/kg/week (Peg-Intron®; Schering-Plough, Kenilworth, NJ, USA) or pegylated-interferon 2a 180 µg/week (Pegasys®; Roche, Basel, Switzerland) subcutaneously, and weight-based ribavirin (1000–1200 mg/day). Patients with HCV genotype 2/3 infection received treatment for either 24 weeks (Ireland) or 48 weeks (Austria), while those with genotype 1/4 infection received treatment for 48 weeks when HCV RNA was negative at week 24 of therapy. The IL28B associated SNP data for the Austrian patients has previously been published [16]. All patients were included for RVR analysis, with RVR defined as undetectable HCV RNA level by week four of treatment. Treatment success i.e. achievement of SVR was defined as undetectable plasma HCV RNA using the sensitive RT-PCR assay 24 weeks post-treatment cessation. Six patients were included in the analysis that achieved an SVR but did not complete the full treatment regimen. HCV genotype, HCV and HIV-1 viral load, CD4+ T cell count, and liver enzymes levels were recorded at baseline.

Table 1

Main clinical characteristics of the population included in on-treatment analysis.

	No SVR (n = 48)	SVR (n = 101)	P value
Gender, M/F	35 (0.729)/13 (0.271)	73 (0.77)/22 (0.23)	NS, P>0.05
Age, years	43.99±0.86	45.40±1.36	NS, P>0.05
HCV Genotype
1	31 (0.65)	38 (0.37)
2	0 (0.00)	8 (0.08)
3	10 (0.21)	49 (0.49)
4	7 (0.15)	5 (0.05)
6	0 (0.00)	1 (0.01)
HCV Genotype 1/4 versus non 1/4	38 (0.792)/10 (0.208)	43 (0.426)/58 (0.574)	P = 0.0000278
HCV VL pre Rx, IU/ml (mean ± SEM)	6433000±1221000	4965000±664700	NS, P>0.05
ALT, U/ml (mean ± SEM)	103.8±9.4	77.2±7.2	NS, P>0.05
AST,U/ml (mean ± SEM)	67±4.85	61±4.4	NS, P>0.05
CD4+ pre Rx, cell counts/ml (mean ± SEM)	509±21.2	510±27.7	NS, P>0.05
HIV VL pre Rx, IU/ml (mean ± SEM)	13400±11380	9830±2062	NS, P>0.05
HAART, yes/no	39 (0.81)/9 (0.18)	59 (0.62)/36 (0.38)	P = 0.0205

Patients who completed a course of pegylated-IFN and Ribavirin therapy were included in the SVR analysis. SVR, sustained virological response; VL, viral load; Rx, treatment; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HAART, highly active antiretroviral therapy; NS, not significant.

Genotyping for KIR 2DS3 and the Associated SNP, rs12979860

Blood was collected in EDTA tubes following standard phlebotomy. DNA was isolated from whole blood, using the Qiamp DNA blood Mini Kit system (Qiagen, Hilden, Germany). The presence or absence of the KIR2DS3 gene was determined using a PCR with sequence specific primers (PCR-SSP) method as described by Vilches et al. [17]. Genotyping for the rs12979860 SNP was performed using the ABI Taqman allelic discrimination kit [12], [18]. For routine quality control purposes, approximately 10% of samples were retyped anonymously, and no mismatches were found.

Statistical Analysis

Continuous variables were presented as mean (± standard error of the mean) unless otherwise stated. Differences between continuous variables were evaluated by means of student’s t-test. Categorical baseline characteristics, genotype, allele and carrier frequency differences and odds ratio trend tests between populations were tested for significance by direct counting using a chi-square (χ 2) by EPI-INFO 3.5.1. Odds ratios (OR) were calculated and 95% confidence intervals are shown. P values less than 0.05 were considered significant. Statistical interaction between KIR2DS3 and IL28B-T was evaluated by multinomial logistic regression (release 16.0; SPSS Inc.). Multinomial logistic regression is an extension of binary logistic regression that allows for more than two categories of the dependent or outcome variable. Baseline characteristics with a P<0.05 in univariate analysis were included as co-variates in multinomial logistic regression analysis and an adjusted odds ratio was generated.

Results

The IL28B SNP, rs12979860, is Associated wtih HCV Treatment Response in a Cohort of HCV/HIV-1 Co-infected Patients

The IL28B associated SNP, rs12979860, predicts both spontaneous and treatment outcomes to HCV infection [9], [12], [19], [20]. The IL28B-C allele is associated with HCV clearance while the IL28B-T allele is associated with a failure to do so. In order to test if the IL28B SNP, rs12979860, predicts responsiveness to HCV therapy in a HCV/HIV-1 co-infected setting, we typed a cohort of patients who had completed PEG-IFN and ribavirin treatment, for their IL28B genotype. Data on a subset of these patients has previously been published [16]. In the current cohort, sixty five patients were homozygous for the IL28B-C allele (CC, 0.436), 70 were heterozygous for IL28B-CT (CT, 0.470), and 14 patients were homozygous for IL28B-T allele (TT, 0.094). These genotypes were in Hardy-Weinberg equilibrium as expected.

Patients were stratified according to whether they achieved SVR following treatment and clinical characteristics of the groups are shown in Table 1. Baseline HCV genotype and HAART were significantly different between patients with SVR versus those that did not achieve SVR. In terms of IL28B analysis, IL28B-CC genotype was found much more frequently among patients with SVR (0.564, n = 57) compared to patients without SVR (0.167, n = 8; see Table 2). Conversely, the presence of the IL28B-T allele (IL28B-CT or IL28B-TT) was significantly over-represented in those patients that did not respond to treatment (0.833, n = 40) compared to those that cleared the virus (0.377, n = 44, P<0.000005). Thus, similar to what we have previously reported in spontaneous clearance [12], [18] and confirming what others have previously reported in HCV treatment response in a subset of this current cohort [18] the IL28B SNP, rs12979860, impacts HCV treatment responsiveness in patients co-infected with HCV and HIV-1.

Table 2

The IL28B SNP, rs12979860, is associated with HCV treatment response in a cohort of HCV/HIV-1 co-infected patients.

	Frequencies		No SVR vs SVR
IL28B Genotype1	No SVR (n = 48)	SVR (n = 101)	χ2 (P)	OR (trend test)
CC	0.167 (8)	0.564 (57)	20.396 (<0.00001)	1
CT	0.666 (32)	0.377 (38)		6.11
TT	0.167 (8)	0.059 (6)		9.67

Patients that completed therapy were genotyped for the IL28B SNP (rs12979860) using a Taqman allele discrimination assay. Genotype frequencies were compared between patients who achieved SVR following treatment (n = 101) and those who did not achieve SVR (n = 48). Differences in frequency distribution between groups were tested for significance by a trend test.

Genotype for a subset of these patients, n = 72, has previously been described (Reference 16)

KIR2DS3 Gene Frequency is Increased in Co-infected Patients that Fail to Achieve SVR

As we had previously found that KIR2DS3 was a genetic locus that predicted increased risk of developing chronic HCV infection, we hypothesised that it may also impact patient responsiveness to HCV treatment. Indeed, this was the case as the frequency of the KIR2DS3 gene was significantly increased in patients that did not achieve SVR following treatment (0.438, n = 21) compared to those who did (0.218, n = 22, P<0.001; OR 2.79; 95% CI 1.25, 6.27, see Table 3). The carrier frequency of the KIR2DS3 gene in the HCV/HIV-1 co-infected patients (0.289, n = 149), was similar to that found in a healthy, normal population (0.221, n = 136) [21].

Table 3

KIR2DS3 gene frequency is increased in co-infected patients that fail to achieve SVR.

	Frequencies		No SVR vs SVR
KIR2DS3	No SVR(n = 48)	SVR(n = 101)	χ2 (P)	OR (CI)
Positive	0.438 (21)	0.218 (22)	7.65 (<0.01)	2.79 (1.75, 6.27)
Negative	0.562 (27)	0.782 (79)

KIR2DS3 was genotyped in our cohort by PCR-SSP. The carrier frequency of KIR2DS3 in 149 HCV/HIV-1 co-infected treated with peg-IFN and ribavirin was compared in 101 patients who achieved SVR following treatment and 48 patients who did not achieve SVR. Differences in frequency populations were tested for significance by χ2 test. Odds ratio with 95% confidence intervals is shown.

The Presence of Both IL28B-T Allele and KIR2DS3 Genetic Loci Significantly Increased the Risk of HCV Treatment Failure

Having identified two host genetic risk factors that modify treatment responsiveness in patients co-infected with HIV-1 and HCV, we examined if the presence of both risk factors influenced treatment outcomes compared to patients presenting with either one or no risk factor. When stratified, there was a significant difference between the groups (P<0.0005, OR 4.44, 95% CI 1.81, 10.96, see Table 4) indicating increased odds of treatment failure in patients having both IL28B-T and KIR2DS3. We therefore tested for potential interaction between these two risk factors. Using logistic regression to assess the independent predictive role of the two genetic loci, the presence of KIR2DS3 became non-significant (OR 3.46, 95% CI 0.759, 15.781, P = 0.109) but the presence of IL28B-T and the presence of both alleles together (i.e., KIR2DS3 carriers and IL28B-T carriers) remained significant. The presence of KIR2DS3 along with IL28-T was associated with a strikingly increased OR in co-infected patients who failed to achieve SVR (Figure 1; OR 23.903, 95% CI 6.363, 89.813, P<0.0001). As HCV genotype and HAART were signifiantly different in univariate analysis, they were included as co-variates in multivariate logistic regression analysis. While HAART lost statistical significance, HCV genotype remained an independent predictor of treatment outcome. Adjusted OR for IL28B and KIR2DS3 are shown in Figure 1. In summary the presence of both risk alleles, KIR2DS3 and IL28B-T, synergised to significantly increase the odds of failing to achieving SVR compared to the presence of either marker alone.

Table 4

The presence of both IL28B-T and KIR2DS3 significantly increased the odds of HCV treatment failure.

Genotype	No SVR (n = 48)	SVR (n = 101)	χ2(P)	OR (CI )
2DS3+T+	0.396 (19)	0.129 (13)	13.77 (<0.0005)	4.44 (1.81, 10.96)
Presence of none or one risk factor	0.604 (29)	0.827 (88)

Patients were stratified according to the carriage of both risk factors (IL28B-T allele and KIR gene 2DS3) compared to either no risk factor or just one present. The frequency of the genotypes between patients that achieved SVR (n = 101) was compared with those that failed to clear virus (n = 48) and tested for significance by χ2 test.

Figure 1

The presence of both KIR2DS3 and IL28B-T alleles synergise to increase the odds of HCV treatment failure.

ORs for KIR2DS3 alone, IL28B-T carriers (CT or TT) alone, and KIR2DS3 with IL28B-T compared with neither risk factor present were calculated from multinominal logisitic regression. The contribution of individual and combined risk factors to the ORs is graphically represented in the bar chart. Positive OR indicates an association with increased odds of treatment failure. aOdds ratio (95% confidence interval). * adjusted OR including HCV genotype and HAART as co-variates.

IL28B-T and KIR2DS3 Identify RVR Negative Patients who Ultimately Fail to Achieve SVR

We investigated if IL28B-T or KIR2DS3 affected RVR in our cohort and found that while KIR2DS3 did not, carriage of IL28B-T was associated with failure to achieve RVR in our patients (Table 5).

Table 5

The IL28B SNP, rs12979860, is associated with RVR in a cohort of HCV/HIV-1 co-infected patients.

	Frequencies		No RVR vs RVR
IL28B Genotype	No RVR (n = 88)	RVR (n = 61)	χ2 (P)	OR (trend test)
CC	0.296 (28)	0.607 (37)	9.807 (<0.005)	1
CT	0.625 (50)	0.328 (20)		3.30
TT	0.114 (10)	0.066 (4)		3.30

Patients were genotyped for the IL28B-associated SNP, rs12979860. Frequencies of the various genotypes were compared between patients that achieved an RVR (n = 61) and those that did not achieve RVR (n = 88) after 4 weeks of treatment. A χ2 trend test was used to compare the data.

Most patients who achieved RVR and completed a full course of HCV therapy achieved SVR (93%; 57/61 such patients in this current cohort). In our cohort, 50% of patients that did not achieve RVR finally achieved SVR while 50% failed to do so. We considered whether IL28B-T or KIR2DS3 was associated with responsiveness to treatment in these HCV/HIV-1 co-infected patients without RVR. RVR negative patients (n = 88) were stratified into four possible “risk genotypes”, according to the presence and/or absence of IL28B-T and KIR2DS3 (see Table 6). Among 20 patients with no host genetic risk factors (i.e. IL28B-CC and KIR2DS3 negative) 18 (90%) cleared virus despite not achieving an RVR. The presence of a single risk factor (either IL28B-T or KIR2DS3) could not sufficiently identify patients likely to achieve SVR in the RVR negative patient group. However, the presence of two host genetic risk factors was strongly associated with treatment failure as only 24% of this group achieved SVR. Thus, host genetic risk factors can increase the potential to identify RVR negative patients that are highly unlikely to respond to therapy.

Table 6

Presence of host genetic risk factors identifies RVR negative patients that will fail to achieve SVR on completion of therapy.

Genotype
IL28B/2DS3	IL28B-CC/2DS3+		IL28B-CC/2DS3-		IL28B-T/2DS3+		IL28B-T/2DS3-
Risk factors	1		0		2		1
Treatment outcome	SVR	No SVR	SVR	No SVR	SVR	No SVR	SVR	No SVR
Counts (n = 88)	4	4	18	2	5	16	17	22
Treatment	Continue		Continue		Stop		Continue

Patients that failed to achieve RVR after 4 weeks of treatment were analysed. Four different host genetic genotypes were identified based on the presence of 2 risk factors (IL28B-T allele, and presence of the NK cell gene KIR2DS3). Patients were stratified according to whether they ultimately achieved SVR or not within each genotype group and the counts obtained are shown. Based on these data, a suggested treatment strategy is shown with respect to supporting patients through treatment or terminating treatment early.

Discussion

We have recently identified an IL28B SNP (rs12979860) and a second immune gene, KIR2DS3, that function as host risk factors predicting failure to spontaneously clear HCV virus by immune mediated mechanisms [12]. In the present study, we investigated if these two host genetic risk factors could also impact patient response to HCV treatment in patients that are co-infected with HIV-1. The IL28B-associated SNP was associated with increased odds of treatment failure in our patients. This supports previously reported data for this SNP in which IL28B-CC was a strong predictor of SVR in HIV-1/HCV co-infected patients [16], [22], [23]. The relative contribution of IL28B major and minor alleles to treatment outcome is not yet clear, although a dominant effect of the IL28B-T allele has been reported for spontaneous and treatment induced viral clearance [9], [12]. Our data suggest that carriage of the IL28B-C allele in co-infected patients conferred a benefit while carriage of IL28B-T allele conferred a risk to the host in terms of treatment response. Understanding the molecular mechanisms involved to explain these findings is a significant challenge as the biological effects of IL28B associated SNPs have not yet been elucidated [24].

We also found that KIR2DS3, an NK cell associated gene, increased the odds of failing to achieve SVR in response to treatment in HCV/HIV-1 infected individuals. There is currently no known function for KIR2DS3 [16] and evidence suggests that it is not expressed at the cell surface [25]. It is likely that KIR2DS3 serves as a genetic marker for a closely related tightly linked KIR gene that mediates the biological effect. Although a mechanism is unclear, presence of KIR2DS3 predicted increased odds of treatment failure in our patient cohort. However, when stratified for independence KIR2DS3 does not appear to be have a role independent of IL28B-T but rather increases its negative effect on treatment outcome. We found the presence of both risk loci, KIR2DS3 and IL28B-T, significantly increases the odds of failing to achieve SVR when compared to the presence of either marker alone and this improves identification of patients with a high likelihood of SVR prior to commencing antiviral therapy. Combining these newly identified host genetic factors with other recognised predictors of SVR (age, baseline HCV-RNA levels, HCV genotype, liver fibrosis stage, pre-treatment IP10 levels) will aid patient management by improving prediction potential of SVR prior to embarking on PEG-IFN and ribavirin treatment. Furthermore, we have confirmed a genetic synergy between IL28B and KIR2DS3 in HCV viral clearance, originally observed in spontaneous clearance and now defined in the treatment induced setting. Although a mechanism for the synergy is not yet known, it is clear that for patients with genotype 1/4 HCV and with both host genetic risk factors, an early and sustained impaired ability to clear virus in response to treatment is evident (see Figure S1). There was no observable impact of host immune genotype on viral kinetics for patients with non-genotype 1/4 HCV that may reflect their well documented rapid response to treatment. These data support the growing body of evidence that the innate immune system plays an important role in HCV clearance.

Achievement of RVR is highly predictive of SVR upon completion of a full duration of PEG-IFN and ribavirin. However, failure to achieve RVR in isolation does not sufficiently discriminate responders from non-responders (50% of RVR negative group achieved SVR in this study) and therefore treatment is continued in all individuals. Identification of factors that predict SVR in these RVR negative patients would significantly improve clinical management of this patient subgroup, and the data presented here provide an important contribution towards this goal. Combining IL28B and KIR2DS3 genotypes increased the likelihood of failing to achieve SVR in the RVR negative cohort of patients. This effect appeared to be independent of HCV genotype although sample numbers were small upon stratification (data not shown). In the RVR negative patients the negative predictive value (indicating correct prediction of treatment failure) of using both risk genetic loci increases to 95.45% (with sensitivity of 90% and specificity of 61,76%) compared to 86.36% (with sensitivity of 78.57% and specificity of 64.41%) for the presence of IL28B-T alone. These data suggest that patients that have achieved a RVR, or have one or no genetic risk factors should continue standard treatment. However, co-infected patients with unfavourable pre-treatment characteristics (i.e. HCV genotype 1/4 and/or presence of at least two host genetic risk factors, see Table 6) who fail to achieve RVR are highly unlikely to achieve SVR. For these patients, where primary outcome of treatment is to obtain SVR and not just secondary gain of histological stability, therapy could be stopped. Individualising care pathways would limit toxicity in those unlikely to respond and lower costs associated with ineffective treatment. These patients could then be prioritised for access to newer non-IFN based direct acting antiviral agents as they become approved in co-infected patients. While the data need to be validated in additional cohorts, the results strongly suggest that host genetic analysis needs to become a routine consideration during management of care pathways in HCV/HIV-1 co-infection.

On treatment HCV kinetic response stratified according to innate immune gene risk factors. Kinetic responses are shown for patients with HCV genotypes 1/4 (A) and non-1/4 genotypes (B). Black squares indicate carriage of 1 or no innate immune gene risk factors; Black triangle, carriage of both IL28B-T and KIR2DS3. Symbols shown mean value and bars show standard error of the mean (SEM).

(TIFF)

Click here for additional data file.